- Home
- TVIV vs PRQR Comparison
TVIV vs PRQR Comparison
Compare TVIV & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVIV | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 244.1M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TVIV | PRQR |
|---|---|---|
| Price | $9.90 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 6.3K | ★ 811.9K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $1.33 |
| 52 Week High | $9.95 | $3.10 |
Technical Indicators
Market Signals| Indicator | TVIV | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 55.83 |
| Support Level | N/A | $1.37 |
| Resistance Level | $9.93 | $1.99 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 63.24 |
Price Performance
Historical ComparisonAbout TVIV Texas Ventures Acquisition IV Corp Class A Ordinary Shares
Texas Ventures Acquisition IV Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.